Study guide
5.1 Pharmacodynamics and Dose-Response
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
5.1 Pharmacodynamics and Dose-Response
Key Takeaways Explain This Topic AI
Affinity (Kd) governs receptor binding, while intrinsic activity determines the maximum effect a drug can produce once bound.
Full agonists achieve Emax; partial agonists plateau below Emax and can act as competitive antagonists in the presence of a full agonist.
Competitive antagonists shift the agonist dose-response curve rightward without reducing Emax; noncompetitive antagonists reduce Emax and are insurmountable.
Therapeutic index equals TD50 divided by ED50; values near or below 2 indicate a narrow, dangerous margin between efficacy and harm.
Tachyphylaxis is an acute loss of response after repeated doses, whereas tolerance develops more slowly and often involves pharmacokinetic or pharmacodynamic adaptation.
Last updated: July 2026
Drug-Receptor Interactions
Most drugs produce effects by binding to specific receptors — cellular macromolecules (usually proteins) that recognize endogenous ligands and translate binding into a biological response. The classic lock-and-key model treats the receptor as a rigid pocket with a fixed shape complementary to the ligand. The more dynamic induced-fit model recognizes that both receptor and ligand undergo conformational changes on binding, which explains how a single receptor can accommodate structurally related ligands and how partial agonists stabilize distinct active states.
Two quantitative properties describe receptor interactions. Affinity is the strength of binding, conventionally expressed as the dissociation constant Kd — the concentration at which 50% of receptors are occupied. Lower Kd means higher affinity. Intrinsic activity (efficacy) is the ability of the bound drug to activate the receptor and generate a response. A drug can bind tightly (high affinity) yet produce no effect (zero intrinsic activity, e.g., a pure antagonist).
Receptor Classifications
Pharmacology classifies receptors by structure and signal transduction mechanism:
- Superfamily Examples Time Course
- G protein-coupled receptors (GPCRs) Adrenergic, muscarinic, opioid, serotonin Seconds
- Ligand-gated ion channels Nicotinic, GABA-A, NMDA, 5-HT3 Milliseconds
- Voltage-gated ion channels Na+, Ca2+, K+ channels Milliseconds
- Enzyme-linked receptors Receptor tyrosine kinases (insulin, EGFR) Minutes to hours
- Intracellular/nuclear receptors Steroid, thyroid, vitamin D receptors Hours
Nuclear receptors act as ligand-activated transcription factors; their delayed onset explains why levothyroxine and corticosteroids take days to weeks to produce clinical effects.
Agonists and Antagonists
A full agonist produces the maximal response the tissue can give (Emax = 1). A partial agonist has intrinsic activity between 0 and 1 — it cannot reach Emax even when all receptors are occupied, and in the presence of a full agonist it behaves as a competitive antagonist, lowering the overall response. Clinical examples include pindolol at beta receptors and buprenorphine at mu opioid receptors. An inverse agonist produces an effect opposite to that of an agonist by stabilizing the inactive conformation of a receptor that exhibits constitutive activity (spontaneous signaling without ligand); examples include naloxone at mu receptors and mirtazapine at H1/5-HT2A receptors.
Antagonists are classified by mechanism:
Competitive (surmountable) — bind reversibly to the same site as the agonist; increasing agonist concentration overcomes the block. The dose-response curve shifts rightward in parallel with no change in Emax.
Noncompetitive (insurmountable) — bind irreversibly or to an allosteric site; the curve shows reduced Emax that cannot be overcome by more agonist.
Physiological — two drugs produce opposing effects through different receptors (e.g., insulin vs. glucagon on blood glucose).
Chemical — one drug binds another directly in solution (e.g., protamine neutralizing heparin, chelators binding heavy metals).
Dose-Response Relationships
The graded dose-response curve (individual subject, log dose on x-axis, effect on y-axis) is a sigmoid curve; it describes potency and efficacy for a single patient. The quantal dose-response curve (population) describes the cumulative proportion of subjects achieving a predefined response at each dose and is used to derive ED50, TD50, and LD50:
- ED50 — dose effective in 50% of the population
- TD50 — dose toxic in 50% of the population
- LD50 — dose lethal in 50% of the population
- Potency vs Efficacy
- Property Definition Clinical Meaning
- Potency Concentration producing 50% of Emax (EC50) Lower EC50 = more potent; affects dose size
- Efficacy Maximum effect achievable (Emax) Determines whether the drug can fully control the disease
A highly potent drug is not necessarily more clinically effective — efficacy is what determines whether the therapeutic goal is achievable. Potency mainly affects the dose required.
Therapeutic Index and Safety
Therapeutic index (TI) = TD50 / ED50 . A larger TI indicates a wider safety margin. Drugs such as penicillin have a very large TI, whereas digoxin, lithium, warfarin, and chemotherapeutics have a narrow TI and require monitoring. The therapeutic window is the range between the minimum effective concentration and the minimum toxic concentration — the practical clinical correlate of TI used in therapeutic drug monitoring.
Spare receptors exist when a maximal response is achieved while only a fraction of receptors are occupied; this signal amplification explains why high-affinity agonists can produce full effects at low receptor occupancy, particularly at GPCRs.
Tachyphylaxis, Tolerance, and Desensitization
Tachyphylaxis is an acute, rapid loss of response after repeated dosing over minutes to hours (e.g., ephedrine, indirect sympathomimetics that deplete norepinephrine stores). Tolerance is a slower loss of response over days to weeks, often involving pharmacokinetic induction (e.g., CYP induction by carbamazepine) or homeostatic receptor downregulation (e.g., opioids). Desensitization is receptor-level refractoriness — rapid phosphorylation and internalization of GPCRs (e.g., beta-agonists in asthma) — and is often reversible within minutes after the agonist is withdrawn.